Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des Myelodysplasies

BACKGROUND: Although lenalidomide is very effective in the treatment of anemia of lower risk myelodysplastic syndromes with 5q deletion (del 5q), concerns have been raised over the fact that this drug could trigger progression to acute myeloid leukemia in some patients. DESIGN AND METHODS: Ninety-fi...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Adès, Lionel, Le Bras, Fabien, Sebert, Marie, Kelaidi, Charikleia, Lamy, Thierry, Dreyfus, François, Eclache, Virginie, Delaunay, Jacques, Bouscary, Didier, Visanica, Sorin, Turlure, Pascal, Bresler, Agnès Guerci, Cabrol, Marie-Paule, Banos, Anne, Blanc, Michel, Vey, Norbert, Delmer, Alain, Wattel, Eric, Chevret, Sylvie, Fenaux, Pierre
Natura: Artigo
Lingua:Inglês
Pubblicazione: Ferrata Storti Foundation 2012
Soggetti:
Original Articles and Brief Reports
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3269480/
https://ncbi.nlm.nih.gov/pubmed/21993675
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2011.045914
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi